Partnership between BC Platforms, Euformatics and Oncompass Medicine selected to provide standardized NGS workflows in oncology for seven major European hospitals

Partnership between BC Platforms, Euformatics and Oncompass Medicine selected to provide standardized NGS workflows in oncology for seven major European hospitals

ZURICH, December 1, 2022 /PRNewswire/ — BC Platforms (BCP), a global leader in healthcare data management and analytics, today announced that, with Finland Euinformatics and Hungary Oncompass Medicine, the BCP-led partnership, has now successfully won the contract for the second phase of development of standardized oncology workflows for a consortium of buyers from seven major hospitals in Central Europe*, represented by Medical University from Graz. This follows the announcement of May 18, 2022 on the three companies that are joining forces to carry out phase 1 of this “Instand-NGS4P”** project.

Instand-NGS4P is a Horizon 2020 funded project that shares BC Platforms’ vision to improve the diagnosis of cancer patients. This is achieved by developing and delivering integrated and standardized workflows for next-generation sequencing (NGS) and integrating information from cancer genetic testing, pharmacogenetic testing and e-medication, to support the medical decision making. The program will take place in three phases until May 2025 with a total pre-commercial procurement budget of approximately EUR 8 million (around $8.2 million).

BC Platforms, Euformatics and Oncompass Medicine worked on designing the solution. After extensive review of reports submitted by various vendors for Phase 1 and Phase 2 applications for prototyping, the BC Platforms-led partnership was awarded the Phase 2 contract. Expertise in areas such as genomic data management, variant interpretation, NGS data quality control and precision oncology was fundamental to the partnership winning the contract.

kurt hitprofessor of pathology at the Medical University of Graz, said, “The first phase of this important project to deliver innovative, patient- and clinical-focused NGS workflows has come a long way since our last announcement in May. The consortium of BC Platforms, Euformatics and Oncompass Medicine was selected from multiple applications, which were evaluated through a multi-stage peer review process, and we look forward to continuing this exciting collaboration in phase two.

Tero SilvolaBC Platforms CEO, said: “I am delighted that the exceptional quality of work on this important Horizon 2020 funded project, the result of our close partnership with the talented teams at Euformatics and Oncompass Medicine, has been recognized with a contract for phase two. . We are proud that our genomic data management platform helps improve healthcare, alongside Euformatics’ expertise in variant interpretation and quality control, and the strong contribution of Oncompass Medicine to the e-medication component of the program.

Tommi KaasalainenCEO of Euformatics, said, “We are thrilled with another win in partnership with BC Platforms, having together deployed clinical solutions in North America, Europeand Asia. Oncompass Medicine has been a great addition to the partnership, bringing significant value. We will continue with this winning trio in phase two of the Instand-NGS4P program, which will rely on the Euformatics Genomics Hub offer in close collaboration with the main European healthcare establishments. »

Professor dr. Istvan PetakFounder and CEO of Oncompass Medicinesaid: “I said in May that we were looking forward to pushing the boundaries, and I’m thrilled with how far we’ve been able to go, working closely with our partners. We want to deliver an end-to-end solution. final solution allowing oncologists to find the right targeted therapy for each cancer patient based on the entire complex molecular profile of their tumor. This partnership will make it easier for hospitals to deploy better NGS services, and patients will have better treatments, long after the project is completed.”

The second phase of the project begins now, with expected results in January 2024. The hospital’s purchasing consortium will then evaluate the production of all Phase 2 contractors and select those who will move on to Phase 3 to eventually deploy and integrate in 2025 two standardized NGS workflows following the program Instand-NGS4P.

* The consortium is made up of hospitals from the Medical University of Graz in AustriaUniversity of Florence and the University of Milano-Bicocca in Italy, Erasmus University Medical center in the NetherlandsChristian-Albrecht University in Kiel and St. Anna Children’s Cancer Research Institute in Germanyand the Center Léon Bérard in France.
** The project is co-financed by European Union grant agreement number 874719.

About BC Platforms

BC Platforms is a global leader in building data networks for the life sciences industry and provides versatile technology platforms for personalized medicine, accelerating the translation of innovations into clinical practice. We convert complex biological information collected in healthcare into actionable insights. Through our innovative technology, we are creating an infinite patient-centric loop between the life sciences and healthcare industries. The data we generate, harmonize and manage, from various biobanks and healthcare institutions, is made accessible to pharmaceutical and biotech companies to enhance their core strengths in research and development. At the same time, we enable the stratification of patients towards targeted therapies, holding the promise of more personalized healthcare.

Our high-performance genomic data discovery and analysis platform enables flexible data integration, secure analysis, and interpretation of molecular and clinical information. We have developed a global network of data partners,, which provides access to high-quality real-world data. This rapidly growing network has a footprint at many sites, including networks of major hospitals, spanning 20 countries on five continents, providing standard care data to over 23 million patients. Our platforms seamlessly facilitate access to highly enriched data for pharmaceutical research and development.

Founded in 1997 as a spin-off from MIT Whitehead, we have a strong scientific heritage underpinned by more than 25 years of working closely with a network of leading researchers, developers, and industry partners. We have global operations with our head office in Zürich, SwitzerlandR&D in Espoo, Finlandand Singaporeas well as a presence in London and Boston. For more information visit our website and follow us on LinkedIn.



View original content: – seven-major-european-hospitals-301690575.html

SOURCE BC Platforms

#Partnership #Platforms #Euformatics #Oncompass #Medicine #selected #provide #standardized #NGS #workflows #oncology #major #European #hospitals

Leave a Comment

Your email address will not be published. Required fields are marked *